LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb. 27, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that it has signed an exclusive option and license agreement with Medical Aesthetics Technology Corporation (“MATC”) for the use of BioSante’s calcium phosphate nanotechnology (CaP) in the field of aesthetic medicine. Under the terms of the option and license agreement, MATC will use BioSante’s CaP technology to develop products for commercialization in the field of aesthetic medicine, specifically, the improvement and/or maintenance of the external appearance of the head, face, neck and body.
